Stock SGBI SANGUI BIOTECH INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Sangui Biotech International, Inc. Other OTC

Equities

SGBI

US80105B1017

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sangui BioTech International Inc.: Significant increase in sales in the first three quarters of the year - Further reduction of the operating loss
EQ
Sangui BioTech International Inc.: Significant increase in sales in the first half of the year - Further reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Sangui BioTech International Inc.: - Sales of USD 41,029 in first quarter - For the first time, positive quarterly result in the company's history
EQ
SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SANGUI BIOTECH INTERNATIONAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
Sangui BioTech International Inc.: Increase in sales in the first quarter of 121% - Highest quarterly sales in the company's history
EQ
Sangui BioTech International Inc.: Sales of USD 69,190 in fiscal year 2022 - Reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Sangui BioTech International Inc.: - Increase in sales in the first nine months of the year - Further reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Sangui BioTech International Inc.: Significant increase in sales in the first half of the year - Further reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Sangui BioTech International Inc.: - Sales of USD 18,560 in first quarter - Reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Sangui BioTech International Inc.: Granulox is awarded the prestigious Prix Galien
EQ
Sangui BioTech International Inc.: - Sales of USD 65,582 in fiscal year 2021 - Reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Sangui BioTech International Inc.: - Granulox(R) - Follow up
EQ
Sangui BioTech International Inc.: - Significant increase in sales in the first nine months - Reduction of operating loss
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SBH Stock
  4. SGBI Stock
  5. News Sangui Biotech International, Inc.
  6. Press Releases